Eli Lilly and Company
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Eli Lilly and Company sits in the top decile of US sponsors by registered trial count (#18 of 15,742 sponsors by registered trial count).
Eli Lilly and Company: 1,341 sponsored US clinical trials, 124 recruiting.
Eli Lilly and Company sponsors 1,341 registered US clinical trials on ClinicalTrials.gov, 124 of them currently recruiting, and 1,029 completed. 459 of these trials are in Phase 3-4 (later-stage) and 861 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 55 trials.
Top-decile sponsor footprint
Eli Lilly and Company ranks in the top decile of sponsors by registered trial count (#18 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,029 of 1,131 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,341 total, page 20 of 27
A Study for Participants With Small-Cell Lung Cancer
NCT01025284
A Study of Semagacestat for Alzheimer's Patients
NCT01035138
A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma
NCT01006252
A Study for Adults With Plaque Psoriasis
NCT01018810
A Study of LY2599506 in Patients With Type 2 Diabetes
NCT01024244
First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin
NCT00982111
A Study Comparing Duloxetine Versus Placebo in Patients Taking a Nonsteroidal Anti-inflammatory Drug (NSAID) for Knee Pain Due to Osteoarthritis
NCT01018680
A Study of Duloxetine in Major Depressive Disorder (MDD) and Associated Painful Symptoms
NCT01000805
A Study of Advanced or Metastatic Non-small Cell Lung Cancer
NCT00988858
Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes
NCT01017731
A Weight Loss Study in Overweight Men and Women
NCT00993421
A Study of LY2801653 in Advanced Cancer
NCT01285037
Study of Participants With Advanced Non-Small Cell Lung Cancer
NCT00948675
A Study of LY573636-sodium in Patients With Metastatic Breast Cancer
NCT00992225
Study in Adolescents With Schizophrenia or Bipolar Disorder
NCT00982020
A Multiple Dose Study of LY2541546 in Healthy Postmenopausal Women
NCT01742091
A Study of Pediatric Participants With Attention Deficit/Hyperactivity Disorder
NCT00965419
A Study in Relapse Prevention of Treatment-Resistant Depression
NCT00958568
Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma
NCT00917384
A Study in Patients With Rheumatoid Arthritis
NCT00966875
The Cymbalta Pregnancy Registry
NCT01074151
Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women
NCT00927186
A Study of Duloxetine in Patients With Osteoarthritis Knee Pain
NCT00945945
Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI)
NCT00910299
A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder
NCT00922636
A Study of LY2189102 in Patients With Type 2 Diabetes
NCT00942188
A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer
NCT00913835
Study of IMC-EB10 in Participant With Leukemia
NCT00887926
Effect of LY2062430 on the Progression of Alzheimer's Disease
NCT00904683
A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver
NCT00906373
Effect of LY2062430 on the Progression of Alzheimer's Disease
NCT00905372
A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab
NCT00845039
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
NCT00882999
A Study for Assessing Treatment of Patients Ages 10-17 With Bipolar Depression
NCT00844857
A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture
NCT00887354
A Study of LY2405319 in Participants With Type 2 Diabetes
NCT01869959
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia Symptoms Who Are Being Treated With Alpha Blockers
NCT00848081
A Study for Participants With Type 2 Diabetes Mellitus
NCT00871572
A Study in the Treatment of Children and Adolescents With Major Depressive Disorder
NCT00849693
A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia
NCT00855582
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
NCT00870870
A Study in the Treatment of Children and Adolescents With Major Depressive Disorder
NCT00849901
A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer
NCT00781911
Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors
NCT00698841
A Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
NCT00840034
A Study for Participants With Pancreatic Cancer
NCT00839332
A Study to Test the Combination of Two Different Kinds of Medications for the Treatment of Diabetes
NCT00853151
An Open Label Extension Study in Participants With Rheumatoid Arthritis
NCT00837811
Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
NCT00843518
A Study in Erectile Dysfunction
NCT00833638
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 517 |
| Phase 2 | 344 |
| Phase 3 | 368 |
| Phase 4 | 91 |
Therapeutic Areas
What is open in the Eli Lilly and Company pipeline
124 recruiting of 1,341 indexed (9% open); 1,029 completed (77%).
Phase mix: 459 late (III/IV) vs 861 early (I/II) (early-phase heavy).
Top condition: Healthy (55 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Eli Lilly and Company: open-pipeline peers nationwide
Peers matched on 1,341 registered trials and 9% open enrollment, not the therapeutic-area sidebar.
Eli Lilly and Company sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,341 trials (± recruiting share)
- GlaxoSmithKline · 1,345 trials · 4% recruiting
- University of Michigan · 1,327 trials · 13% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
- AstraZeneca · 1,285 trials · 12% recruiting
Sponsors near 9% open enrollment (± trial volume)
- Shionogi · 9% recruiting · 54 trials
- University of Kentucky · 9% recruiting · 54 trials
- University of Vermont · 9% recruiting · 162 trials
- Lahey Clinic · 9% recruiting · 43 trials
Related
What to do with this Eli Lilly and Company page
1,341 registered trials is a research-attention snapshot, not an endorsement of Eli Lilly and Company or any single study.
- 124 of Eli Lilly and Company's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy is the condition Eli Lilly and Company studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Eli Lilly and Company pipeline card: 1,341 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.